France· FR:67232080
KYGEVVI 2 g/2 g, poudre pour solution buvable
A medicinal product containing doxribtimine + doxécitine, registered in France by UCB PHARMA BELGIQUE.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DOXRIBTIMINE + DOXÉCITINE
- Manufacturer
- UCB PHARMA BELGIQUE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip13340093033524630 sachet(s) polyéthylène basse densité (PEBD) aluminium polyéthylène téréphtalate (PET)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Doxribtimine + doxécitine in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKYGEVVIUCB Pharma SA, Brusel
- FinlandKYGEVVIUCB Pharma SA
- IrelandKYGEVVI 2 g/2 g powder for oral solutionUCB Pharma S.A.
- IcelandKYGEVVIUCB Pharma S.A.*
- NetherlandsKYGEVVI 2 g/2 g poeder voor drankUCB Pharma S.A.
- SwedenKYGEVVI 2 g/2 g Pulver till oral lösningUCB Pharma S.A.
- United StatesKYGEVVIUCB, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kygevvi
- Liechtenstein · Kygevvi
- Norway · Kygevvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9b682382-0776-44e7-91de-44c83b8589e2 GET /v1/drugs/9b682382-0776-44e7-91de-44c83b8589e2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67232080",
"date_amm": "2026-03-26",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/25/2013",
"substance": "DOXRIBTIMINE + DOXÉCITINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution buvable",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about doxribtimine + doxécitine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.